|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...1617181920212223242526...6566» |
- ||| New trial, Preclinical: Study to Obtain Blood and Voided Urine Samples to Improve the Diagnosis of Melioidosis (clinicaltrials.gov) - Jan 29, 2016
P=N/A, N=3600, Not yet recruiting, Sponsor: Institute of Tropical Medicine, Belgium
- Trial completion: Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity (clinicaltrials.gov) - Jan 28, 2016
P1, N=37, Completed, Sponsor: University of Oxford
Active, not recruiting --> Completed
- ||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion, Trial primary completion date, Pneumococcal vaccines: Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - Jan 28, 2016
P3, N=767, Completed, Sponsor: SK Chemicals Co.,Ltd.
Active, not recruiting --> Completed Enrolling by invitation --> Completed | Trial primary completion date: Apr 2014 --> Oct 2014
- Trial completion: VAST: Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis (clinicaltrials.gov) - Jan 27, 2016
P=N/A, N=300, Completed, Sponsor: University of Pittsburgh
Enrolling by invitation --> Completed | Trial primary completion date: Apr 2014 --> Oct 2014 Recruiting --> Completed
- || Solithera (solithromycin) / Melinta Therap, Fujifilm Holdings
Trial primary completion date: Pharmacokinetics and Safety of Solithromycin in Adolescents and Children (clinicaltrials.gov) - Jan 27, 2016
P1, N=64, Recruiting, Sponsor: Cempra Inc
Recruiting --> Completed Trial primary completion date: Dec 2015 --> Aug 2016
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Jan 26, 2016
P3, N=540, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2015 --> Aug 2016 Trial primary completion date: Mar 2016 --> Sep 2016
- Enrollment closed, Trial primary completion date: NIDIAGDigest: Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders (clinicaltrials.gov) - Jan 26, 2016
P=N/A, N=4000, Active, not recruiting, Sponsor: Swiss Tropical & Public Health Institute
Trial primary completion date: Mar 2016 --> Sep 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016
- ||| Cubicin (daptomycin) / Merck (MSD)
Enrollment closed: Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005) (clinicaltrials.gov) - Jan 22, 2016
P4, N=75, Active, not recruiting, Sponsor: Cubist Pharmaceuticals LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016 Recruiting --> Active, not recruiting
- ||| New trial: Rheumatic Heart Disease Study in Lusaka (clinicaltrials.gov) - Jan 22, 2016
P=N/A, N=1024, Recruiting, Sponsor: University of Zambia
- Zeven (dalbavancin) / RaQualia, AbbVie
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: A P3 Comparator Trial in Community Acquired Bacterial Pneumonia (clinicaltrials.gov) - Jan 22, 2016
P3, N=0, Withdrawn, Sponsor: Durata Therapeutics Inc., a subsidiary of Allergan plc
Recruiting --> Active, not recruiting N=438 --> 0 | Initiation date: Jan 2015 --> Nov 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2016 --> Nov 2016
- Kineret (anakinra) / SOBI
Trial completion, Enrollment change: Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever (clinicaltrials.gov) - Jan 21, 2016
P3, N=25, Completed, Sponsor: Sheba Medical Center
N=438 --> 0 | Initiation date: Jan 2015 --> Nov 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2016 --> Nov 2016 Recruiting --> Completed | N=50 --> 25
- Cubicin (daptomycin) / Merck (MSD)
New P4 trial: IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB (clinicaltrials.gov) - Jan 21, 2016
P4, N=50, Recruiting, Sponsor: Sharp HealthCare
- Trial primary completion date: Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP) (clinicaltrials.gov) - Jan 21, 2016
P2, N=40, Recruiting, Sponsor: Michael Boyle
Recruiting --> Completed | N=50 --> 25 Trial primary completion date: Mar 2016 --> Mar 2017
- || Arbelic (telavancin) / Cumberland
Trial primary completion date: Telavancin Observational Use Registry (TOUR) (clinicaltrials.gov) - Jan 18, 2016
P=N/A, N=1000, Recruiting, Sponsor: Theravance Biopharma Antibiotics, Inc.
Trial primary completion date: Mar 2016 --> Mar 2017 Trial primary completion date: Nov 2016 --> Jun 2018
- |||| Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
Trial primary completion date: Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections (clinicaltrials.gov) - Jan 18, 2016
P3, N=150, Recruiting, Sponsor: Bayer
Trial primary completion date: Nov 2016 --> Jun 2018 Trial primary completion date: Oct 2016 --> Jun 2017
- TicoVac (tick-borne encephalitis vaccine, whole Virus inactivated) / Pfizer
Trial primary completion date: Vaccine Study for Tick-Borne Encephalitis Virus (TBEV) (clinicaltrials.gov) - Jan 18, 2016
P2, N=160, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Oct 2016 --> Jun 2017 Trial primary completion date: Jan 2030 --> Nov 2020
- ||| Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
Enrollment closed: Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier (clinicaltrials.gov) - Jan 16, 2016
P4, N=108, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Trial primary completion date: Jan 2030 --> Nov 2020 Enrolling by invitation --> Active, not recruiting
- |||||| Enrollment open: Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen (clinicaltrials.gov) - Jan 15, 2016
P3, N=1080, Recruiting, Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||| vancomycin / Generic mfg.
Enrollment open: Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis (clinicaltrials.gov) - Jan 15, 2016
P3, N=150, Recruiting, Sponsor: Kurobe LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: Evaluation of a Novel Midstream Urine Collection Technique for Infants in the Emergency Department (clinicaltrials.gov) - Jan 15, 2016
P=N/A, N=150, Completed, Sponsor: Children's Hospital of Eastern Ontario
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||||| Zemdri (plazomicin) / Ionis, Achaogen
Enrollment open, Trial initiation date: EPIC: A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) (clinicaltrials.gov) - Jan 15, 2016
P3, N=530, Recruiting, Sponsor: Achaogen, Inc.
Recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Jan 2016
- New trial: POPH: Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population (clinicaltrials.gov) - Jan 15, 2016
P0, N=621, Not yet recruiting, Sponsor: Université de Montréal
- ||| RPA563 / Ligand, recombinant Protective Antigen Anthrax (rPA) vaccine (Px563L) / Ligand
New P1 trial: A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects (clinicaltrials.gov) - Jan 14, 2016
P1, N=54, Recruiting, Sponsor: Pfenex, Inc
- ||| Trial completion: Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults (clinicaltrials.gov) - Jan 6, 2016
P1, N=52, Completed, Sponsor: Novartis
Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Jan 2016 Active, not recruiting --> Completed
- | Trial completion: A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults. (clinicaltrials.gov) - Jan 6, 2016
P1, N=50, Completed, Sponsor: Novartis
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial completion: Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (clinicaltrials.gov) - Jan 6, 2016
P3, N=558, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Negaban (temocillin) / Eumedica
Trial completion, Gram negative: Temocillin Pharmacokinetic in Hemodialysis (clinicaltrials.gov) - Jan 5, 2016
P4, N=16, Completed, Sponsor: AZ Sint-Jan AV
Active, not recruiting --> Completed Active, not recruiting --> Completed
- IMM-201 / Immodulon
Enrollment change, Nontuberculous mycobacteria: Phase I Trial of DAR-901 (clinicaltrials.gov) - Jan 5, 2016
P1, N=59, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Active, not recruiting --> Completed N=77 --> 59
- | Trial completion: STRIDE: Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis (clinicaltrials.gov) - Jan 5, 2016
P4, N=809, Completed, Sponsor: AIDS Clinical Trials Group
N=77 --> 59 Active, not recruiting --> Completed
- | New P4 trial, Adverse events: Gastrus: The Effect of Probiotic Combination on Helicobacter Pylori Infection in Children (clinicaltrials.gov) - Jan 4, 2016
P4, N=118, Not yet recruiting, Sponsor: University Medical Centre Ljubljana
- Hutruo (bermekimab IV) / J&J
New P2 trial: MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB (clinicaltrials.gov) - Dec 31, 2015
P2, N=20, Recruiting, Sponsor: Evangelos J. Giamarellos-Bourboulis, M.D.
- OligoG CF-5/20 / AlgiPharma
Trial primary completion date: A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection (clinicaltrials.gov) - Dec 30, 2015
P2, N=12, Recruiting, Sponsor: AlgiPharma AS
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Jul 2016
- zoliflodacin (ETX0914) / Entasis Therap, Global Antibiotic Research and Development Partnership
Enrollment closed, Trial primary completion date: Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea (clinicaltrials.gov) - Dec 29, 2015
P2, N=180, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Oct 2015 --> Jul 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jan 2016
- New trial, Surgery: PCR Technique to Identify Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus in Nasal and Respiratory Tract Samples (clinicaltrials.gov) - Dec 29, 2015
P=N/A, N=300, Recruiting, Sponsor: Emilio Bouza
- New trial: Biofilm Formation in Staphylococcus Epidermidis Associated Implant Infections (clinicaltrials.gov) - Dec 29, 2015
P=N/A, N=124, Completed, Sponsor: BG Unfallklinik
- New trial: Validity of Patient-Collected Wet Mounts (clinicaltrials.gov) - Dec 29, 2015
P=N/A, N=40, Recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
- ||||| Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
New P2 trial: Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam (clinicaltrials.gov) - Dec 29, 2015
P2, N=224, Not yet recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- ||| Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Enrollment closed, Pneumococcal vaccines: Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) (clinicaltrials.gov) - Dec 25, 2015
P2, N=690, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Jan 2016 Recruiting --> Active, not recruiting
- Enrollment change: Analysis of Lyme Disease Lesions (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=60, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting N=40 --> 60
- New trial: Early Outcomes of Radical Debridement Versus no Debridement Under Different Surgical Procedures (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=74, Completed, Sponsor: The Second Hospital of Anhui Medical University
- ||| Enrollment open: T2Bacteria Panel Pivotal Study (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=1850, Recruiting, Sponsor: T2 Biosystems
N=40 --> 60 Not yet recruiting --> Recruiting
- GSK4069327A / LimmaTech Biologics
Trial completion: Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a (clinicaltrials.gov) - Dec 22, 2015
P1, N=30, Completed, Sponsor: LimmaTech Biologics AG
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- trimethoprim/sulfamethoxazole / Generic mfg.
Trial initiation date: Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection (clinicaltrials.gov) - Dec 22, 2015
P=N/A, N=139, Completed, Sponsor: Wilford Hall Medical Center
Active, not recruiting --> Completed Initiation date: Apr 2008 --> Jul 2008
- ||| Enrollment open: Biologic Basis Of Increased Susceptibility Of Smokers To Pulmonary Infection With Mycobacterium Tuberculosis (clinicaltrials.gov) - Dec 21, 2015
P=N/A, N=180, Recruiting, Sponsor: Weill Medical College of Cornell University
Initiation date: Apr 2008 --> Jul 2008 Not yet recruiting --> Recruiting
- vancomycin / Generic mfg.
Trial primary completion date: Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation (clinicaltrials.gov) - Dec 18, 2015
P2, N=86, Recruiting, Sponsor: Seoul National University Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Dec 2016
- || Trial primary completion date: Clinical and Microbiologic Characteristics of Cephalosporin-Resistant E. Coli-PITT Protocol (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=150, Active, not recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Trial primary completion date: Risk Factors for Carbapenem-resistant Acinetobacter Baumannii (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- piperacillin sodium/tazobactam sodium / Generic mfg.
Trial primary completion date: Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=1000, Active, not recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- || piperacillin / Generic mfg.
Trial primary completion date: Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=1000, Active, not recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Enrollment open: NCCLS Interpretive Criteria for Salmonella (clinicaltrials.gov) - Dec 18, 2015
P=N/A, N=50, Enrolling by invitation, Sponsor: University of Pittsburgh
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Enrolling by invitation